Effect of mifepristone on abortion access in the United States

Obstetrics and Gynecology

Volumn 114, Issue 3, 2009, Pages 623-630

  Finer, Lawrence B ^a   Wei, Junhow ^a  

^a GUTTMACHER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIFEPRISTONE; MISOPROSTOL;

ARTICLE; DRUG APPROVAL; DRUG MARKETING; DRUG USE; GEOGRAPHIC DISTRIBUTION; GYNECOLOGY; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HUMAN; INDUCED ABORTION; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; OBSTETRICS; POPULATION RESEARCH; PRIORITY JOURNAL; SURGICAL ABORTION; UNITED STATES;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; DRUG APPROVAL; DRUG UTILIZATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MIFEPRISTONE; PREGNANCY; UNITED STATES;

EID: 69549126221     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181b2a74d     Document Type: Article

References (32)

1. Beal MW, Simmonds K. Clinical uses of mifepristone: an update for women's health practitioners. J Midwifery Womens Health 2002;47:451-460
2. Clark WH, Hassoun D, Gemzell-Danielsson K, Fiala C, Winikoff B. Home use of two doses of misoprostol after mifepristone for medical abortion: a pilot study in Sweden and France. Eur J Contracept Reprod Health Care 2005;10:184-191 (Pubitemid 41759279)
3. El-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995;332:983-987
4. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. BJOG 2005;112:1102-1108 (Pubitemid 41632666)
5. Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hum Reprod 2005;20:2348-2354 (Pubitemid 41418530)
6. Kulier R, Gülmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. The Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD002855. DOI: 10.1002/14651858.CD002855.pub3.
7. Marions L. Mifepristone dose in the regimen with misoprostol for medical abortion. Contraception 2006;74:21-25 (Pubitemid 43870273)
8. Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception 2006;74:42-44 (Pubitemid 43866059)
9. Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002;66:247-250 (Pubitemid 35284531)
10. Henshaw SK, Finer LB. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health 2003;35:16-24.
11. Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Results of a large multicenter trial in the United States. Mifepristone Clinical Trials Group. Arch Fam Med 1998;7:360-366
12. Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Am J Obstet Gynecol 2000;182:1292-1299
13. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998;338:1241-1247 (Pubitemid 28216577)
14. Urquhart DR, Templeton AA, Shinewi F, Chapman M, Hawkins K, McGarry J, et al. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study-final results. Contraception 1997;55:1-5.
15. Beal MW. Update on medication abortion. J Midwifery Womens Health 2007;52:23-30.
16. Henderson JT, Hwang AC, Harper CC, Stewart FH. Safety of mifepristone abortions in clinical use. Contraception 2005;72:175-178
17. Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception 2004;70:183-190 (Pubitemid 39119979)
18. Sitruk-Ware R. Mifepristone and misoprostol sequential regimen side effects, complications and safety. Contraception 2006;74:48-55. (Pubitemid 43870274)
19. Talbot M. The little white bombshell. The New York Times July 11, 1999;sect 6:39.
20. Joffe C. Medical abortion in social context. Am J Obstet Gynecol 2000;183:S10-5.
21. Leeman L, Asaria S, Espey E, Ogburn J, Gopman S, Barnett S. Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion? Contraception 2007;76:96-100.
22. Jones RK, Zolna MR, Henshaw SK, Finer LB. Abortion in the United States: incidence and access to services, 2005. Perspect Sex Reprod Health 2008;40:6-16.
23. Strauss LT, Gamble SB, Parker WY, Cook DA, Zane SB, Hamdan S. Abortion surveillance-United States, 2004. MMWR Surveill Summ 2007;56:1-33.
24. Henshaw SK, Kost K. Trends in the characteristics of women obtaining abortions, 1974 to 2004. New York (NY): Guttmacher Institute; 2008.
25. Child TJ, Thomas J, Rees M, MacKenzie IZ. A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. Hum Reprod 2001;16:67-71. (Pubitemid 32058582)
26. Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases. Contraception 2005;71:327-332 (Pubitemid 40602308)
27. Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health 2002;34:154-161
28. Department of Health, United Kingdom. Abortion statistics, England and Wales: 2002. United Kingdom: Government Statistical Service; 2003. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsStatistics/DH-4069635. Retrieved July 15, 2009.
29. Department of Health, United Kingdom. Abortion statistics, England and Wales: 2007. United Kingdom: Government Statistical Service; 2008. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsStatistics/DH-085508. Retrieved July 15, 2009.
30. Rosing MA, Archbald CD. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. J Am Med Womens Assoc 2000;55:183-185
31. Dehlendorf CE, Grumbach K. Medical liability insurance as a barrier to the provision of abortion services in family medicine. Am J Public Health 2008;98:1770-1774
32. National Abortion Federation. Timeline of work to enhance the role of certified nurse-midwives (CNMs), nurse practitioners (NPs), and physician assistants (PAs) in abortion care. Washington (DC): National Abortion Federation; 2006.